Advertisement

Topics

Novartis and MMV initiate Phase IIb trial of KAF156 for malaria in Africa

19:00 EDT 21 Aug 2017 | Net Resources International

Novartis and Medicines for Malaria Venture (MMV) have initiated a Phase IIb clinical trial of KAF156 to treat multidrug-resistant malaria in Africa.

Original Article: Novartis and MMV initiate Phase IIb trial of KAF156 for malaria in Africa

NEXT ARTICLE

More From BioPortfolio on "Novartis and MMV initiate Phase IIb trial of KAF156 for malaria in Africa"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Tropical Medicine
Tropical Medicine is the study of diseases more commonly found in tropical regions than elsewhere. Examples of these diseases are malaria, yellow fever, Chagas disease, Dengue, Helminths, African trypanosomiasis, Leishmaniasis, Leprosy, Lymphatic filaria...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...